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Objective: to present our experience with stent placement in renal arteries in solitary kidneys for treating renal
insufficiency.
Design: retrospective analysis.
Materials: in 26 patients with solitary kidney (17 men, 9 women, mean age: 63 years), presented with renal insufficiency
(se-creat >0.144 mmol/l), stent was placed in a stenosed renal artery. We analysed the clinical outcome, based on the
level of creatinine at 3 months following the procedure. Clinical benefit was considered when there was a decrease
compared to the baseline creatinine by >20% or a stabilisation of the creatinine value (±20% of the baseline).
Results: in 16 of the 26 patients (62%), clinical benefit was achieved. However, 38% of the study population, renal
function continued to deteriorate. Baseline creatinine value was the single best predictor for clinical benefit achievement
(odds ratio: 13; 95% confidence intervals: 1.6–107, p=0.01).
Conclusion: renal stenting results in improvement or stabilisation of renal function in the majority of the patients with
solitary kidneys and renal artery stenosis, presenting with renal insufficiency. Because best outcome was observed mainly
in those patients with not progressed renal insufficiency, intervention should be focused on that group.
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Introduction However, very few other reports on renal artery stent-
ing exist in this subgroup of patients, limiting in this
Atheromatous ischaemic nephropathy is an increas- way the widespread utilisation of this procedure.
We present our experience with the use of Palmazingly prevalent condition, accounting for 14% of
patients undergoing haemodialysis above 50 years of stents to treat patients with ischaemic nephropathy
and solitary kidney.age.1 It is accompanied by the highest mortality among
all the causes of end-stage renal failure.2 The renal
survival is 97% at 2 years for patients with two kidneys
and unilateral atheromatous disease, 82% for bilateral
disease and drops to 45% for patients with reno- Materials and Methods
vascular disease of single kidneys.3 Therefore, it is of
great importance to preserve renal function especially We retrospectively reviewed our experience in our
in the solitary kidney and most clinicians advocate institution, which is a major referral centre in our
revascularisation of these patients. Shannon et al.4 country, with renal artery stenting for treating patients
reported improvement of renal function in approx- with atheromatous ischaemic nephropathy and sol-
imately 43% of patients who underwent percutaneous itary kidneys. During a 5-year period a total of 28
transluminal renal artery stenting (PTR-ST) in a single balloon expandable Palmaz stents (Johnson & Johnson)
kidney with atheromatous renovascular involvement. were deployed in 26 patients, referred to us from
the vascular surgery service after consultation of the
nephrology service. Twenty-one patients had solitary
kidneys due to non-functioning contralateral kidney
∗ Please address all correspondence to: A. Chatziioannou, Radiology as result of progressive atheromatous ischaemic neph-Department, Areteion Hospital, 76 Vas. Sofias Ave., Athens, 11528,
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Table 1. Demographic, clinical, laboratory and radiographic char- patients had more than one artery supplying the single
acteristics of the cohort. kidney; a stent was placed in the major vessel, which
Entire cohort (n=26) also had the greatest stenosis. During the procedure
3000 units of heparin (via the sheath) and 150 mcg
Demographics aliquots of nitroglycerin (directly into the renal artery)Age (years) 63±13
Males (n) 17 (65%) were administered. Completion angiography was per-
formed via a diagnostic catheter (Fig. 1). The totalCo-morbid conditions (n)
Cardiovascular disease 24 (92%) amount of contrast material used, was closely mon-
Hyperlipidaemia 17 (65%) itored during the procedure and never exceeded 50 ccDiabetes mellitus 9 (35%)
(concentration 300 mgI/ml). Only aspirin 300 mg dailySmoking (in the present or past) 21 (81%)
was given after the procedure.Laboratory values
Baseline creatinine (mmol/l) (range) 0.26 (0.14–0.46) Technical success was defined as deployment of the
stent at the desired position with less than 10% residualRadiographic findings (n)
Ostial lesions 18 (69%) intraluminal stenosis in the post intervention angio-
Non-ostial lesions 8 (31%) graphy. Clinical benefit was determined by serial meas-
urements of serum creatinine levels every 2 weeks for
the first 3 months. Clinical benefit was defined as
artery. The remaining 5 had other causes of solitary either improvement (reduction of creatinine by at least
kidney such as surgical removal due to trauma (n= 20% from pre-treatment values) or stabilisation (cre-
2) and tumour (n=3). All procedures were performed atinine within ±20% the pretreatment levels) at 3
for salvage of renal function (serum creatinine months after the procedure. Failure was defined as
[0.144 mmol/lt). Demographic and clinical char- deterioration in serum creatinine by more than 20%
acteristics of the cohort are demonstrated in Table 1. of the pretreatment level.
Comorbid conditions were considered these for which The patients were followed for the determination of
the patients received treatment. the overall survival.
Ultrasonography and diagnostic renal angiography
were performed in all patients, prior to referral for
intervention. Patients with severe intrarenal athero-
sclerotic vascular disease, as identified by the an- Statistical analysis
giogram or with kidney length of <8.0 cm by U.S.
measurement, were excluded from the intervention. Logistic regression model was developed to determine
A femoral approach was used in 23 patients. A high which of the variables was associated with outcome.
brachial or axillary puncture was used in 3 patients The exponential of coefficient of the variables was the
due to severe stenosis of iliac or common femoral variables’ odds ratio; 95% confidence interval of the
arteries. A 7-French introducer sheath was routinely odds ratio was calculated to test for significant as-
used. An initial flush injection of the abdominal aorta sociations. Significant associations were considered
was performed in all patients with a pigtail catheter when p<0.05.
and a rate of 12 cc/s for 1 s. Nonionic contrast material
was used in all patients.
Subsequently, selective renal angiography was per-
formed. A stenosis was considered haemodynamically Results
significant if it was >60% diameter narrowing. The
degree of arterial stenosis was the ratio of the diameter Technical success was achieved in all patients with
less than 10% residual intraluminal stenosis after stentof the narrowest lumen of the artery to the nearest
distal normal lumen unaffected by poststenotic di- placement. Problems during the procedures were en-
countered in two patients. One stent was positionedlatation. Eighteen lesions (69%) were ostial, defined as
those occurring within 2 mm of the aortic lumen. initially proximal to the balloon during insertion man-
oeuvre, but was eventually repositioned on the sameBalloon angioplasty was performed initially, in all
cases. Subsequent stent placement was performed with balloon with minimal inflation and placed on the
correct site. A second stent was projecting more thanthe standard technique previously reported in the
literature, which aimed to cover the lesion leaving 3 mm into the aortic lumen (Fig. 2) in the early stages of
the study. Although there was concern about thrombus1–3 mm of stent protruding into the aorta for ostial
lesions. Fifteen or twenty millimeter long stents moun- formation, no such complication occurred. Two stents
were placed too far distally and failed to cover ostialted on a 5 or 6 mm balloon were deployed. Three
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Fig. 1. (a) Pre and (b) post Palmaz stent (6 mm×15 mm) placement in a severe stenosis of the renal artery in a solitary kidney. Patient
had left nephrectomy due to trauma. Intraparenchymal vascular disease was insignificant. Pretreatment creatinine was 0.2 mmol/l.
Patient’s renal function status was improved significantly after the intervention (0.138 mmol/l).
3 demonstrates the creatinine levels of all the patients
from before the procedure until 3 months after, in 4
weeks intervals. All 10 patients who became worse
begun haemodialysis within 14 months or died sec-
ondary to cardiac failure, pulmonary edema or stroke.
Two patients required early (within 1 month) dialysis.
Both had moderate intrarenal arterial disease with
baseline creatinine higher than 0.32 mmol/lt. The 1-
and 2-year survival rate were 80% and 45%, re-
spectively.
Logistic regression model was used for the de-
Fig. 2. (a) Post intervention angiogram shows significant projection of the stent into the aortic lumen. (b) 6 months follow up angiogram
confirms location and patency of the stent. The patient did not experience any sequelae of this misplacement.
lesions. In those cases a second overlapping stent was
deployed more proximally. Complications occurred in
2 patients (8%). One patient developed thrombosis of
the brachial artery despite the anticoagulation, and
required surgical thrombectomy. The other major com-
plication was an extensive hematoma at the puncture
site of the femoral artery, which required surgical
evacuation. There were no periprocedural deaths.
Minor puncture complications (small haematomas,
transient median nerve paresis) occurred in 3 patients.
At 3 months follow-up clinical improvement was
achieved in 9 (35%) patients and serum creatinine was termination of the predictive values for achievement
of clinical benefit, of the following variables: baselinestabilised in 7 (27%) additional patients. Deterioration
in renal function occurred in 10 (38%) patients. Figure creatinine, sex, diabetes, ostial vs. non-ostial lesions,
Eur J Vasc Endovasc Surg Vol 23, January 2002
A. Chatziioannou et al.52
0
0.6
Time of follow-up
C
re
at
in
in
e 
le
ve
ls
 (
M
m
ol
/L
t)
0.4
0.2
12 weeks8 weeks4 weeksBaseline
(0.14–0.32)
(0.27–0.46)
0.27
9
7
Fig. 3. Creatinine levels of all patients up to 3 months following the procedure.
and diameter of stent. From these variables only the may be the reason why many series reported no
baseline creatinine was found to be predictive of the improvement of renal function following PTRA.13
clinical outcome at 3 months (odds ratio: 13; 95% Dorros et al.14–16 and Rundback et al.17 noted quite
confidence interval: 1.6–107; p=0.01). The remaining significant benefit for renal function after stent place-
of the variables did not show any predictive value. ment. In their series patients with lower initial serum
creatinine had higher rates of clinical benefit. In ad-
dition, Rundback also described acceptable clinical
benefit for the patients group with higher initial cre-Discussion
atinine levels. Boisclair et al.18 reported renal artery
stenting after failed balloon angioplasty, with at leastExisting data suggest high likelihood of deterioration
similar midterm improvement of renal function toof renal function in patients with untreated ischaemic
those of successful primary balloon angioplasty, andnephropathy.5 The natural history of renal insufficiency
overall better results compared to previous reports.due to renal artery stenosis is usually progressive
Additionally several other reports19,20 exist, that showdeterioration of renal function.6 Strandess7 studied
favourable technical success of renal artery stenting inforty-four patients and concluded that loss of renal
both ostial and non ostial lesions.mass is an important consequence of high-grade renal
In heightened high risk for renal insufficiency areartery stenosis (>60%).
patients with significant renal artery stenosis and oc-The role of renal artery stenting remains to be clearly
clusion of the contralateral renal artery.3 For thesedefined. Available data suggest that renal artery stent-
patients loss of their single kidney would result ining is particularly appropriate in ostial atheromatous
permanent haemodialysis. Thus, it is extremely im-lesions. Cicuto et al.8 describes two types of ostial
portant to aggressively treat this group of patients.lesions. One arises because of a plaque within the
Pattison et al.21 reported 33 patients with singlerenal artery origin, in the other the plaque arises within
kidneys and atherosclerotic renovascular diseasethe aorta and encroaches the origin of the renal artery.
treated with PTRA. Improvement in renal functionThese two types cannot be distinguished by angio-
occurred in 67% of those patients. However, ostialgraphy. Angioplasty alone, of the aortic type, displaces
versus non-ostial lesions were not specified andrather than disrupts the plaque, so elastic recoil is
high, resulting in significant residual stenosis.9–12 This patients with reversible causes or prerenal uremia
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were included in the study. Donovan et al.22 reported thrombosis (this may be due to continuous IV anti-
coagulation during the first post PTR-St day). Never-a 58% improvement of renal function in 17 elderly
theless appropriate surgical back up is especiallypatients with single kidney, but follow-up was short,
essential when performing PTR-St in single kidneys.limited to the time of hospital discharge or death.
In conclusion, our results correlate with previousShannon et al.4 reported the results of stent placement
studies, indicating improvement or stabilisation ofin 21 patients with single kidney. In that study 70%
renal function in most patients after PTR of solitaryof patients treated, benefit from stenting. Joffre et al.23
kidneys. However, in patients with masked renal in-and Hennequin et al.24 reported similar results but have
sufficiency results were dismal.small number of solitary kidneys, 7 and 4 respectively.
Rees et al.25 reported a multi-center study for ostial
stenting in renal arteries, but the number of solitary
kidneys was not clearly stated. He presented a 73% References
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